Loop Capital analyst Andrew Wolf lowered his price target on Rite Aid to $1.35 from $1.75 and kept his Hold rating after its Q2 results, saying that while the Pharmacy Services segment showed improved sales profitability, this was offset by lower profitability in Retail Pharmacy. The analyst added that the discount on the Rite Aid stock relative to the broader pharmacy group is "appropriate" given its "high debt leverage and subscale operations". Wolf further notes that the board's caving to shareholder pressure to cancel the Albertsons deal was a mistake directly linked to the 28% decline in the stock price since August 8th.